By continuing to browse our site you agree to our use of cookies, revised Privacy Policy and Terms of Use. You can change your cookie settings through your browser.
I agree
Search Trends
SITEMAP
Copyright © 2024 CGTN. 京ICP备20000184号
Disinformation report hotline: 010-85061466
SITEMAP
Copyright © 2024 CGTN. 京ICP备20000184号
Disinformation report hotline: 010-85061466
AstraZeneca relies on its R&D center in Shanghai to promote innovation and will launch at least 100 new medicines in China in the next five years, achieving mutual interests with Chinese collaborators, said Sharon Barr, EVP of Biopharmaceuticals R&D of global pharmaceutical giant AstraZeneca, in an interview with CGTN.